Agenus encouraged by early HerpV results

Lexington, MA-based Agenus reported promising Phase I results of its recombinant therapeutic vaccine HerpV for the treatment of genital herpes in a study published in the journal Vaccine. The developer is planning a Phase II trial of the drug in 2012 to test the vaccine on viral shedding in patients infected with HSV-2. "We are very encouraged by these clinical results as published literature suggest that cellular immunity needs to be stimulated for successful treatment of genital herpes--a physically painful and emotionally debilitating disease that affects one in six adults in the U.S.," noted lead author Anna Wald. Agenus release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.